← 返回

癌症免疫治疗的进展:历史视角、当前发展和未来方向

英文原题:Advances in cancer immunotherapy: historical perspectives, current developments, and future directions.

查看英文原题

Advances in cancer immunotherapy: historical perspectives, current developments, and future directions.

PubMed 2025/05/07(内容时间) Mol Cancer Q1 · IF 42.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

癌症免疫治疗,包括实验性治疗和标准治疗,已成为一种利用免疫系统抑制肿瘤的有前景的方法。实验性策略,包括新型免疫治疗和临床前模型,正在积极探索中,而已确立的治疗方法,如免疫检查点抑制剂(ICIs),已在临床环境中广泛应用。这篇综合性综述探讨了癌症免疫治疗的历史演变、潜在机制和多样化策略,重点介绍了其临床应用和正在进行的临床前进展。综述深入探讨了抗癌免疫的基本组成部分,包括树突状细胞激活、T细胞致敏和免疫监视,同时讨论了免疫逃逸机制带来的挑战。关键免疫治疗策略,如癌症疫苗、溶瘤病毒、过继细胞转移和ICIs,被详细讨论。

此外,还探讨了纳米技术、细胞因子、趋化因子和佐剂在提高免疫治疗精准性和疗效中的作用。联合治疗,特别是将免疫治疗与放疗或化疗相结合的治疗,展现出协同潜力,但需要谨慎管理以减少副作用。还探讨了影响免疫治疗结果的新兴因素,包括肿瘤异质性、肠道微生物群组成以及基因组和表观遗传修饰。

此外,分析了免疫逃逸和治疗耐药的分子机制,重点关注非编码RNA和表观遗传改变的贡献,以及创新的干预策略。本综述强调近期的临床前和临床进展,尤其关注旨在优化患者预后的生物标志物驱动方法。免疫治疗相关毒性、在实体瘤中疗效有限以及生产限制等挑战被突出为未来研究的关键领域。个性化治疗和新型递送系统的进展被提出作为增强治疗效果和可及性的途径。通过整合多学科的见解,本综述旨在加深对癌症免疫治疗的理解和应用,最终促进更有效且更广泛可及的治疗方案。

展开英文摘要原文

Cancer immunotherapy, encompassing both experimental and standard-of-care therapies, has emerged as a promising approach to harnessing the immune system for tumor suppression. Experimental strategies, including novel immunotherapies and preclinical models, are actively being explored, while established treatments, such as immune checkpoint inhibitors (ICIs), are widely implemented in clinical settings.

This comprehensive review examines the historical evolution, underlying mechanisms, and diverse strategies of cancer immunotherapy, highlighting both its clinical applications and ongoing preclinical advancements.

The review delves into the essential components of anticancer immunity, including dendritic cell activation, T cell priming, and immune surveillance, while addressing the challenges posed by immune evasion mechanisms. Key immunotherapeutic strategies, such as cancer vaccines, oncolytic viruses, adoptive cell transfer, and ICIs, are discussed in detail.

Additionally, the role of nanotechnology, cytokines, chemokines, and adjuvants in enhancing the precision and efficacy of immunotherapies were explored. Combination therapies, particularly those integrating immunotherapy with radiotherapy or chemotherapy, exhibit synergistic potential but necessitate careful management to reduce side effects. Emerging factors influencing immunotherapy outcomes, including tumor heterogeneity, gut microbiota composition, and genomic and epigenetic modifications, are also examined.

Furthermore, the molecular mechanisms underlying immune evasion and therapeutic resistance are analyzed, with a focus on the contributions of noncoding RNAs and epigenetic alterations, along with innovative intervention strategies. This review emphasizes recent preclinical and clinical advancements, with particular attention to biomarker-driven approaches aimed at optimizing patient prognosis.

Challenges such as immunotherapy-related toxicity, limited efficacy in solid tumors, and production constraints are highlighted as critical areas for future research. Advancements in personalized therapies and novel delivery systems are proposed as avenues to enhance treatment effectiveness and accessibility. By incorporating insights from multiple disciplines, this review aims to deepen the understanding and application of cancer immunotherapy, ultimately fostering more effective and widely accessible therapeutic solutions.

论文信息

作者
Zhang M、Liu C、Tu J、Tang M、Ashrafizadeh M、Nabavi N、Sethi G、Zhao P
第一作者单位
Department of Surgical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.China
通讯作者单位
Department of General Medicine, The 2nd Affiliated Hospital of Harbin Medical University, No. 246 Xuefu Road, Harbin, 150081, China. liushijian@hrbmu.edu.cn.China
文献类型
综述 · 历史回顾
期刊
Molecular cancer2025 May 7
原文标识
PubMed 40336045 · DOI 10.1186/s12943-025-02305-x